上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02607 上海医药

未开盘 09-01 16:08:13

11.560

+0.200

+1.76%

最高11.580	最低11.370	成交量225.42万
今开11.490	昨收11.360	日振幅1.85%
总市值428.64亿	流通市值106.24亿	总股本37.08亿
成交额2,599万	换手率0.25%	流通股本9.19亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"上海医药","latestPrice":11.56,"timestamp":1788250093007,"preClose":11.36,"halted":0,"volume":2254200,"delay":0,"changeRate":0.017605633802816996,"floatShares":919072704,"shares":3708000000,"eps":1.7961201161388458,"marketStatus":"未开盘","change":0.2,"latestTime":"09-01 16:08:13","open":11.49,"high":11.58,"low":11.37,"amount":25993795,"amplitude":0.018486,"askPrice":11.56,"askSize":8100,"bidPrice":11.54,"bidSize":1700,"shortable":3,"etf":0,"ttmEps":1.5002511221057417,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788312600000},"marketStatusCode":0,"adr":0,"listingDate":1305820800000,"exchange":"SEHK","adjPreClose":11.36,"dividendRate":0.045354,"openAndCloseTimeList":[[1788226200000,1788235200000],[1788238800000,1788249600000]],"volumeRatio":1.434576879352548,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":16.39,"timestamp":1788246000000,"preClose":16.25,"halted":0,"volume":11994100,"delay":0,"premium":"-39.53"}},"requestUrl":"/m/hq/s/02607","defaultTab":"news","newsList":[{"id":"2664686315","title":"股市必读：上海医药新发布《上海医药集团股份有限公司关于磷酸芦可替尼片获得批准生产的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664686315","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664686315?lang=zh_cn&edition=full","pubTime":"2026-09-02 01:40","pubTimestamp":1788284423,"startTime":"0","endTime":"0","summary":"公司公告汇总：上海医药下属常州制药厂有限公司磷酸芦可替尼片获国家药监局批准生产，系国内第二家获批企业，此前仅诺华在境内供应；2025年该药国内医院采购额达7.168亿元。公司公告汇总上海医药集团股份有限公司关于磷酸芦可替尼片获得批准生产的公告上海医药集团股份有限公司下属常州制药厂有限公司收到国家药品监督管理局颁发的《药品注册证书》，磷酸芦可替尼片获得批准生产。中国境内此前仅有瑞士诺华制药生产该药品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200001987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601607","BK0175","BK0209","BK0188","BK0028","BK0020","BK0196","BK0184","BK0097","BK0183","BK0012","BK0099","BK0187","BK1197","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664546854","title":"上海医药上半年营收超1400亿元 应收账款规模有所扩张","url":"https://stock-news.laohu8.com/highlight/detail?id=2664546854","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664546854?lang=zh_cn&edition=full","pubTime":"2026-09-01 21:26","pubTimestamp":1788269162,"startTime":"0","endTime":"0","summary":"近日，上海医药（601607.SH）披露2026年半年报。在医药流通行业整体仍处于调整期的背景下，公司扣非归母净利润实现两位数增长，主业盈利韧性凸显，公司应收账款规模随业务拓展有所扩张，资产质量与运营效率的平衡成为新课题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609013861720732.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609013861720732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02607","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129926556","title":"上海医药更新2026年8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1129926556","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129926556?lang=zh_cn&edition=full","pubTime":"2026-09-01 16:42","pubTimestamp":1788252143,"startTime":"0","endTime":"0","summary":"上海医药集团股份有限公司于2026年9月1日发布了截至2026年8月31日的股份变动月报表。报告显示，公司在本报告期内无新增发行、购回、注销或库藏股活动，整体股本结构保持不变。根据公告，截至2026年8月31日，公司法定注册股本维持为人民币3,708,361,809元。具体来看，H股股本数量为919,072,704股，面值为每股人民币1元，总额为人民币919,072,704元，与上月末保持一致；A股股本数量为2,789,289,105股，面值为每股人民币1元，总额为人民币2,789,289,105元，较上月末无变动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663207390","title":"上海医药：磷酸芦可替尼片获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2663207390","media":"第一财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663207390?lang=zh_cn&edition=full","pubTime":"2026-08-31 16:10","pubTimestamp":1788163841,"startTime":"0","endTime":"0","summary":"【上海医药：磷酸芦可替尼片获得批准生产】上海医药公告，近日，公司下属常州制药厂有限公司收到国家药品监督管理局颁发的关于磷酸芦可替尼片的《药品注册证书》，该药品获得批准生产。磷酸芦可替尼片适用于骨髓纤维化、移植物抗宿主病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313860097178.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313860097178.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","BK0209","BK0183","BK1197","601607","BK0196","BK0028","BK0097","BK0184","02607","BK0188","BK0020","BK0012","BK0099","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663439190","title":"每周股票复盘：上海医药（601607）H1营收增4.15%但净利降21.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663439190","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663439190?lang=zh_cn&edition=full","pubTime":"2026-08-30 07:49","pubTimestamp":1788047349,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，上海医药报收于16.41元，较上周的16.19元上涨1.36%。本周，上海医药8月26日盘中最高价报16.59元。本周关注点业绩披露要点：上海医药2026年上半年主营收入1474.7亿元，同比上升4.15%；归母净利润35.04亿元，同比下降21.4%。第二季度单季主营收入722.08亿元，同比上升1.95%；单季度归母净利润20.87亿元，同比下降33.24%；单季度扣非净利润12.39亿元，同比上升48.17%。上海医药对上海上实集团财务有限公司截至2026年6月30日的风险状况进行评估。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000004025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02607","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663016306","title":"上海医药（601607）2026年中报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2663016306","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663016306?lang=zh_cn&edition=full","pubTime":"2026-08-29 06:06","pubTimestamp":1787954805,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期上海医药发布2026年中报。根据财报显示，上海医药增收不增利。截至本报告期末，公司营业总收入1474.7亿元，同比上升4.15%，归母净利润35.04亿元，同比下降21.4%。本文数据来源于上海医药2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900010487.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601607","BK0188","BK0175","BK0196","BK1197","BK0097","BK0184","BK0209","BK0028","BK0020","BK0183","02607","BK0099","BK0012","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662748085","title":"上海医药（601607）披露2026年半年度利润分配方案，8月27日股价下跌0.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662748085","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662748085?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:18","pubTimestamp":1787840329,"startTime":"0","endTime":"0","summary":"截至2026年8月27日收盘，上海医药报收于16.27元，较前一交易日下跌0.91%，最新总市值为603.35亿元。该股当日开盘16.39元，最高16.46元，最低16.18元，成交额达1.55亿元，换手率为0.34%。近日，上海医药集团股份有限公司召开第九届董事会第四次会议，审议通过《2026年半年度利润分配方案》。董事会授权沈波先生负责实施利润分配相关事宜。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700055380.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1197","BK0175","BK0099","BK0097","BK0183","BK0196","BK0184","BK0020","BK0188","BK0028","BK0012","BK0209","02607","BK0187","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194704726","title":"上海医药（02607）公布半年报及分红预案：上半年净利35.04亿元，拟现金分红3.71亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1194704726","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194704726?lang=zh_cn&edition=full","pubTime":"2026-08-27 19:11","pubTimestamp":1787829110,"startTime":"0","endTime":"0","summary":"上海医药8月28日在港交所发布海外监管公告，披露公司第九届董事会第四次会议决议、2026年半年度利润分配方案及关联财务公司风险评估结果，核心信息如下：。– 2026年上半年，公司实现合并归属于上市公司股东的净利润35.04亿元。– 以2026年6月30日的总股本3,708,361,809股为基数，拟向全体股东每10股派发现金红利1.00元（含税），合计派发3.71亿元。– 截至2026年6月30日，上海上实集团财务有限公司资产总额134.70亿元，负债总额119.83亿元，所有者权益14.86亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662449709","title":"上海医药(02607.HK)公布中期业绩 归母净利润约35.04亿元 同比减少21.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662449709","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662449709?lang=zh_cn&edition=full","pubTime":"2026-08-27 19:05","pubTimestamp":1787828726,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1197","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662069297","title":"上海医药2026年中报：工业创新提速、商业转型增效","url":"https://stock-news.laohu8.com/highlight/detail?id=2662069297","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662069297?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:43","pubTimestamp":1787827421,"startTime":"0","endTime":"0","summary":"截至报告期末，上海医药处于临床申请受理及后续阶段的在研新药管线合计61项，其中创新药49项，形成梯次接续的优质创新管线格局。截至目前，上海医药累计486个品种入选国家基药目录。报告期内，上海医药紧扣数字化转型、创新药商业化、精益化运营三大核心主线，持续优化商业业务结构，各核心板块实现高质量增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=95Tc3N%2F8UZc%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK0099","BK0188","BK0187","BK0209","BK0184","BK0028","BK1197","BK0020","BK0183","BK0097","601607","BK0196","02607","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662706944","title":"上海医药2026年上半年归母净利润同比下降21.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662706944","media":"北京商报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662706944?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:23","pubTimestamp":1787826206,"startTime":"0","endTime":"0","summary":"8月27日，上海医药发布2026年半年度报告。上半年，公司实现营业收入1474.7亿元，同比增长4.15%；归属于上市公司股东的净利润为35.04亿元，同比下降21.4%；归属于上市公司股东的扣除非经常性损益的净利润为24.77亿元，同比增长17.98%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608273856573872.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608273856573872.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["601607","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661827678","title":"上海医药(02607)拟挂牌转让上海上药新特东铵大药房51%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2661827678","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661827678?lang=zh_cn&edition=full","pubTime":"2026-08-24 20:26","pubTimestamp":1787574401,"startTime":"0","endTime":"0","summary":"上海医药(02607)公布，公司全资子公司上药控股有限公司拟通过产权交易所以公开挂牌方式转让所持控股子公司上海上药新特东铵大药房有限公司(以下简称“标的公司”)51%股权，挂牌转让价格拟定为人民币1.785亿元。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggaonew/ganggugongg6.jpg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggaonew/ganggugongg6.jpg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0012","601607","BK0028","BK0175","BK0020","BK0196","BK0209","BK0184","BK1197","BK0099","BK0183","BK0187","BK0188","BK0097","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661024308","title":"股市必读：上海医药（601607）8月21日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2661024308","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661024308?lang=zh_cn&edition=full","pubTime":"2026-08-24 01:18","pubTimestamp":1787505494,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，上海医药报收于16.19元，下跌2.82%，换手率0.7%，成交量19.49万手，成交额3.17亿元。董秘最新回复投资者： 上海医药的公众号发文称上海医药的进口业务多年处于全国领先地位，拥有包括Keytruda、Opdivo等在内的诸多进口新药总代权。2025年新引进进口总代品规28个，涵盖21家全球知名企业。当日关注点交易信息汇总：8月21日主力资金净流出2682.1万元，占总成交额8.46%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400000853.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0099","601607","02607","BK0184","BK0196","BK0012","BK0097","BK0187","BK0188","BK0209","BK0175","BK0020","BK0183","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661264382","title":"上海医药：公司进口总代业务多年处于全国领先地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2661264382","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661264382?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:16","pubTimestamp":1787307366,"startTime":"0","endTime":"0","summary":"证券之星消息，上海医药08月21日在投资者关系平台上答复投资者关心的问题。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100033889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0209","601607","BK1197","BK0188","BK0020","BK0028","BK0184","02607","BK0183","BK0099","BK0196","BK0175","BK0097","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660400182","title":"上海医药：公司益生菌产品已搭建起覆盖多元消费场景的完善大健康产品矩阵","url":"https://stock-news.laohu8.com/highlight/detail?id=2660400182","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660400182?lang=zh_cn&edition=full","pubTime":"2026-08-20 17:27","pubTimestamp":1787218029,"startTime":"0","endTime":"0","summary":"公司在益生菌赛道已取得积极的研发成果和市场应用，我们关心的是，现下在此方面是否还有进一步拓展？公司的益生菌产品已经搭建起覆盖多元消费场景的完善大健康产品矩阵。未来，公司将依托研发与供应链优势，持续深耕益生菌赛道，打造更具竞争力的国产益生菌品牌，为大众健康生活贡献更多力量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000030745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0097","BK0183","BK0187","BK0020","02607","BK0188","BK0196","BK1197","BK0099","BK0209","601607","BK0175","BK0184","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176376913","title":"财报前瞻｜上海医药本季度营收预测缺口待补，机构观点分歧扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=1176376913","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176376913?lang=zh_cn&edition=full","pubTime":"2026-08-20 08:59","pubTimestamp":1787187588,"startTime":"0","endTime":"0","summary":"上海医药将于2026年08月27日发布最新季度财报，预计分销业务仍为收入核心，市场关注费用效率与毛利结构变化对利润弹性的影响。由于缺乏工具层面的季度预测数据，当前市场一致预期无法直接量化展示；公司上一季度财报中未见对本季度的营收、毛利率、净利润或净利率、调整后每股收益的明确预测，故不展示具体预测数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜上海医药本季度营收预测缺口待补，机构观点分歧扩大","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164128835","title":"上海医药（02607）发布公告","url":"https://stock-news.laohu8.com/highlight/detail?id=1164128835","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164128835?lang=zh_cn&edition=full","pubTime":"2026-08-17 17:06","pubTimestamp":1786957572,"startTime":"0","endTime":"0","summary":"2024年X月XX日，上海医药（02607）发布公告，就相关事项进行说明。公告的具体内容以公司在交易所披露的文件为准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658922400","title":"上海医药：自2025年起已启动应收账款专项管理工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2658922400","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658922400?lang=zh_cn&edition=full","pubTime":"2026-08-12 15:33","pubTimestamp":1786520031,"startTime":"0","endTime":"0","summary":"证券之星消息，上海医药08月12日在投资者关系平台上答复投资者关心的问题。公司始终高度重视现金流安全、应收账款管理与资产负债结构优化，坚持审慎稳健的财务管控原则，保障公司持续健康运营。在应收账款管理方面，自2025年起，公司已启动应收账款专项管理工作，在工业端实行“一司一策”、在商业端实行“一院一策”，结合不同区域制定差异化管控策略。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200021104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0209","601607","BK0097","BK0175","BK0183","BK0196","02607","BK0099","BK0184","BK0187","BK0012","BK0020","BK0188","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657565215","title":"股市必读：上海医药新发布《上海医药集团股份有限公司关于奥美拉唑碳酸氢钠干混悬剂（I）获得批准生产的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657565215","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657565215?lang=zh_cn&edition=full","pubTime":"2026-08-05 03:08","pubTimestamp":1785870494,"startTime":"0","endTime":"0","summary":"公司公告汇总：上海医药下属上药信谊药厂奥美拉唑碳酸氢钠干混悬剂获国家药监局批准生产，已投入研发费用约593.55万元，2025年该药品中国大陆医院采购金额为1,569万元。公司公告汇总上海医药集团股份有限公司关于奥美拉唑碳酸氢钠干混悬剂获得批准生产的公告上海医药下属上海上药信谊药厂有限公司收到国家药品监督管理局颁发的《药品注册证书》，奥美拉唑碳酸氢钠干混悬剂获批生产。该药品用于活动性十二指肠溃疡和胃食管反流病的短期治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500002486.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0187","BK0196","BK0188","02607","BK0209","BK0097","BK0020","BK1197","BK0183","BK0184","601607","BK0012","BK0175","BK0099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656539305","title":"股市必读：上海医药新发布《上海医药集团股份有限公司关于奥美拉唑碳酸氢钠干混悬剂（I）获得批准生产的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656539305","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656539305?lang=zh_cn&edition=full","pubTime":"2026-08-04 01:29","pubTimestamp":1785778149,"startTime":"0","endTime":"0","summary":"公司公告汇总：上海医药下属上药信谊药厂奥美拉唑碳酸氢钠干混悬剂获国家药监局批准生产，已投入研发费用约593.55万元，2025年该药品中国大陆医院采购金额为1,569万元。公司公告汇总上海医药集团股份有限公司关于奥美拉唑碳酸氢钠干混悬剂获得批准生产的公告上海医药集团股份有限公司下属上海上药信谊药厂有限公司收到国家药品监督管理局颁发的《药品注册证书》，奥美拉唑碳酸氢钠干混悬剂获得批准生产。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400001273.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0209","BK0188","BK0183","BK0097","BK0099","BK0175","BK0184","BK0196","BK1197","601607","BK0187","02607","BK0028","BK0020","BK0012"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.shaphar.com.cn","stockEarnings":[{"period":"1week","weight":0.0114},{"period":"1month","weight":-0.0383},{"period":"3month","weight":0.0353},{"period":"6month","weight":0.0601},{"period":"1year","weight":-0.0028},{"period":"ytd","weight":0.0517}],"compareEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":-0.0214},{"period":"3month","weight":-0.0118},{"period":"6month","weight":0.0003},{"period":"1year","weight":-0.0112},{"period":"ytd","weight":-0.0117}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海医药集团股份有限公司是一家主要从事医药分销业务的中国公司。该公司主要经营四个业务分部。工业分部主要从事药品及保健品的研发、生产和销售。分销分部主要从事向医药制造商及配药商提供分销、仓储和其他增值医药供应链解决方案及相关服务。零售分部主要从事经营及加盟零售药店网络。其他分部主要从事其他业务。该公司主要在国内市场经营其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.533333,"avgChangeRate":0.005822},{"month":2,"riseRate":0.533333,"avgChangeRate":0.014993},{"month":3,"riseRate":0.533333,"avgChangeRate":0.00953},{"month":4,"riseRate":0.533333,"avgChangeRate":0.000651},{"month":5,"riseRate":0.466667,"avgChangeRate":-0.003721},{"month":6,"riseRate":0.5,"avgChangeRate":-0.010249},{"month":7,"riseRate":0.375,"avgChangeRate":-0.010293},{"month":8,"riseRate":0.375,"avgChangeRate":0.007397},{"month":9,"riseRate":0.375,"avgChangeRate":0.013393},{"month":10,"riseRate":0.266667,"avgChangeRate":-0.02141},{"month":11,"riseRate":0.466667,"avgChangeRate":0.029699},{"month":12,"riseRate":0.533333,"avgChangeRate":-0.012572}],"exchange":"SEHK","name":"上海医药","nameEN":"SH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(02607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,02607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(02607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}